141 related articles for article (PubMed ID: 17172417)
1. Topoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexes.
Sordet O; Goldman A; Pommier Y
Mol Cancer Ther; 2006 Dec; 5(12):3139-44. PubMed ID: 17172417
[TBL] [Abstract][Full Text] [Related]
2. Apoptotic topoisomerase I-DNA complexes induced by staurosporine-mediated oxygen radicals.
Sordet O; Khan QA; Plo I; Pourquier P; Urasaki Y; Yoshida A; Antony S; Kohlhagen G; Solary E; Saparbaev M; Laval J; Pommier Y
J Biol Chem; 2004 Nov; 279(48):50499-504. PubMed ID: 15448130
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis.
Sordet O; Liao Z; Liu H; Antony S; Stevens EV; Kohlhagen G; Fu H; Pommier Y
J Biol Chem; 2004 Aug; 279(32):33968-75. PubMed ID: 15178684
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic topoisomerase I-DNA complexes induced by oxygen radicals and mitochondrial dysfunction.
Sordet O; Khan QA; Pommier Y
Cell Cycle; 2004 Sep; 3(9):1095-7. PubMed ID: 15326388
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase I requirement for death receptor-induced apoptotic nuclear fission.
Sordet O; Goldman A; Redon C; Solier S; Rao VA; Pommier Y
J Biol Chem; 2008 Aug; 283(34):23200-8. PubMed ID: 18556653
[TBL] [Abstract][Full Text] [Related]
6. Neutral Porphyrin Derivative Exerts Anticancer Activity by Targeting Cellular Topoisomerase I (Top1) and Promotes Apoptotic Cell Death without Stabilizing Top1-DNA Cleavage Complexes.
Das SK; Ghosh A; Paul Chowdhuri S; Halder N; Rehman I; Sengupta S; Sahoo KC; Rath H; Das BB
J Med Chem; 2018 Feb; 61(3):804-817. PubMed ID: 29290109
[TBL] [Abstract][Full Text] [Related]
7. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
8. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A
Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760
[TBL] [Abstract][Full Text] [Related]
10. New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I/II but reveal different p53-dependency in inducing G2/M arrest and apoptosis.
Tian QT; Ding CY; Song SS; Wang YQ; Zhang A; Miao ZH
Biochem Pharmacol; 2018 Aug; 154():255-264. PubMed ID: 29753750
[TBL] [Abstract][Full Text] [Related]
11. Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32.
Adjei PN; Kaufmann SH; Leung WY; Mao F; Gores GJ
J Clin Invest; 1996 Dec; 98(11):2588-96. PubMed ID: 8958222
[TBL] [Abstract][Full Text] [Related]
12. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
Ling YH; Andersson BS; Nelson JA
Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
[TBL] [Abstract][Full Text] [Related]
14. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Ellis AL; Nowak B; Plunkett W; Zwelling LA
Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
[TBL] [Abstract][Full Text] [Related]
15. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptotic cell death by DNA topoisomerase II inhibitors.
Negri C; Bernardi R; Donzelli M; Scovassi AI
Biochimie; 1995; 77(11):893-9. PubMed ID: 8824770
[TBL] [Abstract][Full Text] [Related]
17. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
18. Distinct steps in DNA fragmentation pathway during camptothecin-induced apoptosis involved caspase-, benzyloxycarbonyl- and N-tosyl-L-phenylalanylchloromethyl ketone-sensitive activities.
Sané AT; Bertrand R
Cancer Res; 1998 Jul; 58(14):3066-72. PubMed ID: 9679972
[TBL] [Abstract][Full Text] [Related]
19. An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.
Hong G; Kreuzer KN
Mol Cell Biol; 2000 Jan; 20(2):594-603. PubMed ID: 10611238
[TBL] [Abstract][Full Text] [Related]
20. Detection of apoptosis induced by topoisomerase inhibitors and serum deprivation in syrian hamster embryo cells.
Alexandre S; Rast C; Nguyen-Ba G; Vasseur P
Exp Cell Res; 2000 Feb; 255(1):30-9. PubMed ID: 10666331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
